Please assess the completion status of the following clinical trial:

Trial Title: Zoledronate With or Without Thalidomide in Treating Patients With Early Stage Multiple Myeloma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of multiple myeloma (MM)~  * Previously untreated asymptomatic disease~ * No requirement for immediate chemotherapy for active MM, such as hypercalcemia from myeloma or painful bone lesions~* No solitary plasmacytoma~* Measurable or evaluable disease as defined by one of the following:~  * Serum monoclonal protein ≥ 1.0 g by protein electrophoresis~ * More than 200 mg of monoclonal protein in the urine by 24-hour electrophoresis~ * Measurable soft tissue plasmacytoma by physical exam with ruler or by MRI or positron emission tomography/CT scan~    * If the only measurable lesion is the plasmacytoma, it must be ≥ 1.5 cm in 1 dimension~* Must have ≥ 10% plasma cells as measured on the bone marrow aspirate, bone marrow biopsy, or labeling index~* No amyloidosis~PATIENT CHARACTERISTICS:~* Performance status 0-2~* Absolute neutrophil count ≥ 1,500/mm³~* Platelet count ≥ 100,000/mm³~* Hemoglobin ≥ 8.0 g/dL~* Creatinine ≤ 2.0 mg/dL (elevation above normal range should not be felt to be related to myeloma)~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use 2 methods of effective contraception 4 weeks before, during, and for 4 weeks after completion of study treatment~* No uncontrolled infection~* No other active malignancy~* No New York Heart Association class III or IV heart disease~* No pre-existing neuropathy ≥ grade 2~* No concurrent major dental work~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* Prior corticosteroids (for nonmalignant disorders) allowed~* Prior therapy with experimental agents not shown to have significant activity in MM, such as clarithromycin, dehydroepiandrosterone, and anakinra allowed~* No prior thalidomide or corticosteroids for MM~* No more than 3 doses of IV zoledronate or pamidronate within the past 12 months~* At least 3 months since prior radiotherapy, including radiotherapy for solitary plasmacytoma~* No concurrent oral bisphosphonate therapy for osteoporosis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm I: Thal/ZLD (Type: EXPERIMENTAL): Thalidomide (Thal) + Zolendronic acid (ZLD)
- Arm II: ZLD (Type: EXPERIMENTAL): Zoledronic acid (ZLD)

Based on this trial design, predict the completion outcome and termination type (if applicable).